Mosquitoes Bred to Carry Bacteria Sharply Cut Dengue in Brazil Trial
A four-year experiment in a Brazilian city tested whether mosquitoes carrying a bacterium that does not hurt people could shield schoolchildren from viruses.
A four-year experiment in a Brazilian city tested whether mosquitoes carrying a bacterium that does not hurt people could shield schoolchildren from viruses.
Scientists combined biobank records from several continents to search for the biology behind a painful condition. The work guides future research and does not yield a test.
Health authorities in a southeastern city are retracing one patient's meals and movements after a confirmation that took more than ten days to complete.
A St. Louis court has cleared a two-decade payment plan meant to settle current and future weed killer lawsuits, though some claims remain outside the deal.
Federal regulators turned down the company's application for deramiocel and pointed to problems in how a key study was run. Capricor stock fell sharply after hours.
Researchers say a protein already used in Alzheimer's research could one day help diagnose a brain disease now confirmed only at autopsy, but the early results come with big caveats.
A Princess Cruises voyage out of Fort Lauderdale has a gastrointestinal outbreak with no identified cause, and the ship is not due back in port until Nov. 23.
The agency cleared a new RNA-based drug for adults with an autoimmune muscle disease, and it comes with a restricted-access safety program tied to vaccination.
Regulators cleared a once-daily pill for a rare inherited disorder, offering the first approved option aimed at the neurological side of the illness.
OpenAI's new healthcare agents operate patient-chart software and insurer portals, and the company's own tests found nearly all sampled tasks clinically safe.
The telehealth company is offering longevity treatments that regulators have not approved, riding a federal policy shift that outside scientists say outpaces the research.
The agency says the program is meant to cut duplicate reviews abroad, and it starts with a narrow set of HIV-related approvals before a planned expansion.
A trial of video-guided home exercise found young people improved sooner than with stretching, but the advantage was limited to those who began soon after injury.
The once-daily pill is cleared for adults who have already tried other targeted drugs, and the approval came ahead of the agency's original target date.
The agency cleared a spinal-canal injection that it says is the first therapy shown to help patients with this inherited disorder live longer.
A federal alert covers ready-to-eat foods carried by vending machines and workplace break rooms, and officials say more products may be added.
Novartis wins a new U.S. use for its psoriasis and arthritis drug, giving adults with an inflammatory condition an option besides long-term steroids.
Two UN agencies say a new global review finds wider health risks from everyday chemicals, yet most substances on the market have never been screened for the hazard.
A drugmaker pulled a single batch of a widely used heart and blood pressure medicine from the U.S. market, saying metal pieces may have slipped into the capsules.
The first trial over cancer claims tied to hair-relaxer products ended early with a confidential deal, leaving thousands of similar lawsuits pending.
An FDA decision lets adults with schizophrenia-related illness or bipolar disorder use Igalmi, a film that dissolves in the mouth, at home during agitation episodes.
A Nov. 16, 2026, rule also eases electronic copies through personal health apps and sets later compliance deadlines.
Giredestrant, paired with everolimus, slowed the cancer in people who carry a frequent resistance mutation.
Health teams aim to reach more than 49,000 young children in Syria's Deir ez-Zor province after three polio cases were recorded around al-Mayadin.
Draft advice for England's NHS would extend a seven-minute capsule test, which gathers cells without a hospital endoscopy, to more people with chronic acid reflux.
Eli Lilly released early figures on Nov. 14 from obesity drug trials, including an experimental combination shot and Zepbound in teenagers, ahead of full results.
The Mine Safety and Health Administration on Nov. 10 proposed changing how mines test for silica dust and how violations are cited, drawing sharp reactions.
A national report puts the per-person cost above $10,000 for the first time, but health policy experts question whether the money is buying patients better care.
The agency said slowing tumor growth was not enough without proof that patients lived longer, a setback for a closely watched type of cancer drug.
Researchers in Beijing built a drug-delivering comb for pattern baldness, but the device has yet to be tried on a single human scalp.
The once-daily drug becomes the third of its class cleared for a tumor that can stiffen and damage joints, after a trial showed most patients' tumors shrank.
An Italian study of more than 80,000 patients found a sharp gap between people who stayed on the drugs and those who stopped, but researchers urge caution.
The guidance favors lower-cost human insulin and regular blood sugar checks, and it is written to work even in emergencies and poor clinics.
The Eli Lilly-owned developer behind the work is already testing a human version in patients whose cholesterol stays high on standard drugs.
Freedom of information figures show the obesity drugs reaching some patients younger than 12, and the totals leave out private and hospital prescriptions.
A Roche antibody already used for blood cancers and lupus kidney disease beat an older off-label drug in a two-year trial.
The decision rests on a late-stage trial in which the drug pairing lowered the risk of death by 42% versus the comparison group.
Stanford researchers built a score from the brains of exceptional older adults and of patients with the disease, then tested it on healthy people.
Researchers say the protein fragment could one day help track a brain disease that can now be confirmed only after death.
An animal sedative spreading through the illegal drug supply can trigger withdrawal that standard treatments do not control, a doctors' group warned.
A company working to let people control devices with their thoughts has stopped adding patients while it reworks its hardware.
Regulators cleared the first daily tablet in a popular class of obesity medicines, giving the U.S. drugmaker a lead over a rival still waiting on a similar decision.
A fast-track drug review pilot appears to have stalled, even as the health department says the project has not been shut down.
Community clinics that tested thousands of people each year are looking for new money after a long-running federal award was allowed to lapse.
The group now tells most men to get a regular blood test, a shift from a long-standing emphasis on talking the choice over with a doctor first.
A new federal survey looks at how Americans actually take the popular diabetes and weight-loss drugs, and why many depart from their prescriptions.
The findings prompted an apology from NHS Grampian’s chief executive, while Scotland’s health secretary is considering further steps.
Two selected teams will develop research data and a domestically made drug product, but the announcement describes groundwork rather than patient trials.
Survey responses also point to sleep loss and reluctance to seek senior advice among doctors training in the specialty.
Henricus G. Ruhé, a psychiatry researcher at Radboud, said: “Our results cannot predict that a certain drug will be effective in an individual.”
The research compares an expanded approach to diagnosis with a widely used measure, raising questions about how obesity is assessed in clinical care.
The wearable is one of two digital approaches assessed for tic disorders, while access and the evidence base remain unsettled.
The borrowing model gives residents a way to try a lamp and related guidance without paying its retail price upfront.
The WHO director-general says insecurity is obstructing the response, while delayed payments risk strikes and community tension.
New research points to uneven provision and different costs for people funding care themselves; final recommendations are due next summer.
The agreement offers a way forward for a service disrupted by a long-running dispute over job grading.
A local vaccination appeal follows an increase in flu cases, while national surveillance shows different trends across measures of activity.
The condition can be difficult to recognize because its symptoms may resemble those of other illnesses.
The proposal would give local decision-makers a needle-free treatment option to assess for people with severe allergic reactions.
Hospitals have been asked to conserve a particularly important blood group while the transfusion service seeks more donors.